Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01828268|
Recruitment Status : Recruiting
First Posted : April 10, 2013
Last Update Posted : April 28, 2017
|Condition or disease|
Since the clinical application of anti-retroviral therapy (ART) in 1997, the life expectancy of HIV infected patients has been prolonged greatly. However,side effects of ART including metabolic abnormalities have become the main factors influencing patients' quality of life. Among which the abnormal lipid metabolism plays an important role. Meanwhile, metabolic conditions differ from patients applying to different combinations of ART drugs,life style and clinical conditions.
Metabolomics can measure the dynamic metabolic responses of the body to stimuli or modifications. Using nuclear magnetic resonance (NMR) as tools can systematically analyse the process of lipid metabolism. Metabolomics fingerprinting can be defined as the complete complement of small molecule (< 1500 Da) metabolites found in a specific cell, body fluid, organ or organism.
Therefore, the study of the impact of metabolic changes and anti-retroviral therapy (ART), life style and clinical conditions is of importance in enhancing the adherence and improving the clinical outcomes of HIV infected patients.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Metabolic Fingerprintings and Metabolic Dynamics After HIV Infection:Impact of Metabolic Changes and Anti-Retroviral Therapy, Life Style and Clinical Conditions|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2020|
100 confirmed HIV-1 infected patients who meet inclusion criteria.
- Dyslipidemia [ Time Frame: Dyslipidemia events from admission to discharge(Up to 6 months) ) ]
- Lipoatrophy [ Time Frame: Lipoarophy events from admission to discharge (up to 6 months) ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828268
|Contact: Hua JIANG, PhDemail@example.com|
|Contact: Bing CAI, Master||+86-28-88424391|
|Sichuan Academy of Medical Sciences,Sichuan Provincial Hospital, Metabolomics and Mutidisciplinary Laboratory||Recruiting|
|Chengdu, Sichuan, China, 610101|
|Contact: Hua JIANG, PhD +86-28-88424391 firstname.lastname@example.org|
|Principal Investigator: Jin PENG, Master|
|Study Chair:||Hua JIANG, PhD||3Sichuan Academy of Medical Science, Sichuan Provincial People's Hospital, East Branch, Metabonomics and Multidisciplinary Laboratory|
|Principal Investigator:||Jin PENG, Master||3Sichuan Academy of Medical Science, Sichuan Provincial People's Hospital, East Branch, Metabonomics and Multidisciplinary Laboratory|